GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound ...

CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

The platform also features a rapid, five-day manufacturing process that significantly improves production efficiency while ...

FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in ...

DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...

Werewolf Therapeutics (HOWL) shared clinical and preclinical data at the 2024 Society for Immunotherapy of Cancer’s 39th Annual Meeting, ...

Duality Biologics Ltd. presented preclinical data on DB-1419, a potentially first-in-class bispecific antibody-drug conjugate (ADC) consisting of a humanized antibody targeting B7-H3 and PD-L1 ...